Bionote

About Bionote

Bionote is a South Korean biotechnology company that develops and manufactures in-vitro diagnostic products for both animal and human health, with a primary focus on the veterinary market. Founded by Dr. Young-Sik Cho, who holds degrees in veterinary medicine and biochemistry from Seoul National University, the company leverages its expertise in diagnostic reagents and production. Bionote, along with its affiliate SD Biosensor, has grown into a global diagnostic entity.

The company's business model is centered on providing point-of-care testing (POCT) solutions to veterinarians, enabling rapid and accurate in-clinic diagnostics. This is achieved through their flagship Vcheck line of quantitative immunoassay analyzers and a broad menu of biomarker tests for canine, feline, and equine patients. Key products include the Vcheck F series analyzers, which use fluorescent europium technology for high sensitivity in detecting cardiac, inflammatory, pancreatic, and endocrine conditions. Bionote also offers rapid diagnostic kits under the Anigen Rapid brand and human-use rapid tests like the NowCheck for respiratory diseases. Revenue is generated through the sale of these analyzers and the associated single-use test kits to veterinary clinics and distributors worldwide, with a presence in over 80 countries. In 2023, Bionote signed a significant distribution agreement with Covetrus, a major US-based animal pharmaceutical distributor, to supply its Vcheck F products, aiming to expand its market share in North America and Europe.

Significant milestones include the launch of the Vcheck series in 2016, the establishment of Bionote USA in 2019, and surpassing 23,000 cumulative global sales for Vcheck analyzers by 2025. The company operates with ISO 9001 and ISO 13485 certifications and possesses a biosafety level 3 (BSL-3) research facility, a unique asset for a private company in this sector. The company is publicly held and listed on the Korea Exchange (KRX).